Kyowa XLH therapy approved in EU

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) and partner Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said

Read the full 134 word article

User Sign In